CSIMarket Company Name, Ticker, Customers, else..
 
Eiger Biopharmaceuticals Inc   (EIGR)
Other Ticker:  
 
 
Price: $1.7250 $-0.18 -9.211%
Day's High: $1.9 Week Perf: 4.55 %
Day's Low: $ 1.66 30 Day Perf: -75.97 %
Volume (M): 138 52 Wk High: $ 14.34
Volume (M$): $ 238 52 Wk Avg: $7.33
Open: $1.90 52 Wk Low: $0.20



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -75
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Eiger Biopharmaceuticals Inc
Eiger Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company's pipeline includes therapies for diseases such as hepatitis delta virus (HDV) infection, COVID-19, and lymphedema. Eiger Biopharmaceuticals aims to provide innovative treatment options for patients with few or no approved treatment options. They utilize a precision medicine approach, leveraging scientific expertise and advanced technologies to develop therapies that specifically target the underlying disease mechanisms.


   Company Address: 2155 Park Boulevard Palo Alto 94306 CA
   Company Phone Number: 272 6138   Stock Exchange / Ticker: NASDAQ EIGR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Eiger Biopharmaceuticals Inc

Reviving the Magic: Eiger Biopharmaceuticals Inc Announces Unprecedented Breakthroughs during the July to September 30 2023 Time-Frame



Eiger Biopharmaceuticals Inc, a leading Biotechnology & Pharmaceuticals firm, revealed its financial results for the July to September 2023 period. The company showcased a substantial reduction in its loss per share, highlighting progress in their financial performance. However, a decline in revenue and a significant drop in stockpiles raise concerns about future prospects. Let's delve into the context of these financial results and examine the current state of Eiger Biopharmaceuticals Inc.
Positive Earnings and Reduced Loss per Share:
In Q3 FY2023, Eiger Biopharmaceuticals Inc demonstrated a noteworthy enhancement in its financial performance. The company reported a decrease in loss per share from $-0.62 a year ago to $-0.41 per share, reflecting a positive trend. Moreover, earnings per share also improved, moving from $-0.47 per share in the previous quarter to $-0.41 per share.
Eiger Biopharmaceuticals Inc

Promising Future for Eiger Biopharmaceuticals Inc as Q2 2023 Revenue Soars by 13.493%

Eiger Biopharmaceuticals Inc, a company in the Biotechnology & Pharmaceuticals industry, has shown significant improvement in its financial performance during the second quarter of 2023. Despite the overall revenue decline in the sector, Eiger Biopharmaceuticals Inc reported an impressive increase in top-line growth.
Compared to the previous year's financial reporting period, the company managed to reduce its loss per share from $-0.51 to $-0.47. Additionally, its earnings per share (EPS) improved from $-0.52 to $-0.47. These positive developments indicate a promising future for the company.
Eiger Biopharmaceuticals Inc

Eiger Biopharmaceuticals Inc Reports Slight Improvement in Q1 2023 Financial Results, but Deficit Widens to $-0.52 per Share

Eiger Biopharmaceuticals Inc, a leading biopharmaceutical company, recently released its financial results for the January to March 31, 2023 interval, and the report was a mixed bag of good and bad news.
The company suffered a net loss of $-0.52 per share, which is a slight improvement compared to the $-0.64 per share loss recorded a year ago. However, the company's deficit surged heavily from the $-0.46 per share loss recorded in the previous reporting period.






Eiger Biopharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com